The Effect of Ovamax on Oocyte Quality

The Effect of Ovamax on Oocyte Quality in Women Undergoing IVF

Oocyte quality is a basic parameter that affects embryo quality and therefore it influences the outcome of assisted reproduction. It has been suggested that oocyte quality is improved by the intake of vitamins and antioxidants.

Ova-Max is a dietary supplement that consists of vitamins, minerals and antioxidants which improve women's oocytes by preventing oxidative stress. Specifically, Ovamax includes Chasteberry, Melatonin, Myo-Inositol, Folic Acid, Co-Enzyme Q10, Vitamin E, L-Arginine, Grape seed extract and Alpha-lipoic Acid. The purpose of this study is to evaluate the influence of Ova-max intake on oocyte quality in women undergoing In Vitro Fertilization.

According to the research hypothesis the administration of Ova-Max for three months increases oocyte quality in women undergoing intracellular sperm injection after ovarian stimulation and oocyte retrieval.

Study Overview

• Status: Terminated
• Conditions: Infertility; Female
• Intervention / Treatment: Other: Ova-max; Other: placebo

Detailed Description

Randomisation

This study is a blind randomized control trial to evaluate the association between Ova-Max intake and the quality of oocytes retrieved after ovarian stimulation. Randomization will be performed at least three months prior to initiation of treatment and patients will be assigned to either Ova-max or placebo by a computer-generated randomization list.

Ovarian Stimulation

A standard ovarian stimulation protocol for all patients will be followed with 200-300 IU of recombinant FSH and GnRH antagonist starting on day 5 of stimulation.

Induction of final oocyte maturation will be performed by recombinant hCG or GnRH agonist. Women who are planned for fresh embryo transfer, will be administered subcutaneous progesterone for luteal phase support starting on the day of oocyte retrieval.

Oocyte Quality Assessment

After oocyte retrieval the cumulus cells of the Cumulus Oocyte complex (COC) are removed and quality of all mature, metaphase II (MII) oocytes is assessed according to the following parameters:

1. Oocyte shape
2. Oocyte size
3. Ooplasm characteristics
4. Structure of the perivitelline space (PVS)
5. Zona pellucida (ZP) and
6. Polar body (PB) morphology

Each parameter is graded as worst (-1), average (0), or best (1) and a total oocyte score (TOS) is calculated by summing up individual parameter assessments.

The maximal TOS of an oocyte, therefore, could be +6, the lowest -6.

The 6 individual parameters are assessed in detail as follows:

1. Oocyte shape (-1): poor oocyte morphology (dark general oocyte coloration and/or ovoid shape) (0): almost normal (less dark general oocyte coloration and less ovoid shape) (+1): normal
2. Oocyte size (-1): abnormally small or large oocyte (0): almost normal size (+1): oocyte size was within normal range
3. Ooplasm characteristics (-1): very granulated and/or very vacuolated cytoplasm and/or demonstrated several inclusions (0): slightly granular and/or demonstrated only few inclusions (+1): absence of granularity and inclusions
4. Structure of the perivitelline space (PVS) (-1): abnormally large PVS, absence of PVS or very granular PVS (0): moderately enlarged PVS and/or small PVS and/or a less granular PVS (+1): normal size PVS with no granules
5. Zona pellucida (ZP) (-1): very thin or thick ZP (0): small deviation from normal (+1): normal zona
6. PB morphology (+1): flat and/or multiple PBs, granular and/or either abnormally small or large PB (0): fair but not excellent PB (+1): normal size and shape of PB

After having assessed the TOS of all MII oocytes, the Mean Oocyte Score (MOS) of the patient is calculated by dividing the sum of all TOS of the patient by the number of her oocytes.

Statistical analysis

Group sample sizes of 79 and 79 achieve 80% power to detect a difference of -1.0 between the null hypothesis that both group TOS means are -1.1 and the alternative hypothesis that the mean TOS of the Ova-Max group is -0.1, with known group standard deviations of 2.2 and 2.2 and with a significance level (alpha) of 0.05000 using a two-sided Mann-Whitney test assuming that the actual distribution is uniform

• Study Type: Interventional
• Enrollment (Actual): 97
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Greece
  • Central Macedonia
    • Thessaloníki, Central Macedonia, Greece, 54631
      • Papageorgiou Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients less than 46 years of age
• ICSI for fertilisation to allow evaluation of oocyte quality

Exclusion criteria:

• Women with endometriosis
• Women with only one ovary
• More than two previous IVF cycles
• Use of testicular sperm
• Intake of other dietary supplements
• Poor responders

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; placebo	Other: placebo; use placebo 3 months prior to treatment initiation
Active Comparator: Ova-max; antioxidant, dietary supplement	Other: Ova-max; use Ova-max 3 months prior to treatment initiation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean oocyte score	The sum of the total oocyte scores of the patient divided by the number of her oocytes. Oocytes is assessed according to the following parameters: Oocyte shape; Oocyte size; Ooplasm characteristics; Structure of the perivitelline space (PVS); Zona pellucida (ZP) and; Polar body (PB) morphology Each parameter is graded as worst (-1), average (0), or best (1) and a total oocyte score (TOS) is calculated by summing up individual parameter assessments. The maximal TOS of an oocyte, therefore, could be +6, the lowest -6.	1-3 hours after oocyte retrieval

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of fertilised oocytes	number of oocytes of a woman that are fertilised divided by the total oocyte injected with sperm	16-18 hours after fertilisation
Blastulation rate	the number of embryos that have reached blastocyst stage divided by the number of fertilised oocytes	day 5 after fertilisation
Pregnancy rate	the number of women who got pregnant divided by the number of women who underwent embryo transfer	6 weeks after embryo transfer
Total number of COCs collected	total number of cumulus oocyte complexes collected from each woman	immediately after oocyte retrieval
Percentage of mature oocytes	number of mature oocytes of a woman divided by her total oocyte number	2-4 hours after oocyte retrieval

Collaborators and Investigators

• Sponsor: Aristotle University Of Thessaloniki
• Collaborators: Eugonia IVF Unit, Athens, Greece
• Investigators: Principal Investigator: Efstratios M Kolibianakis, Professor, Aristotle University Thessaloniki

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2021
• Primary Completion (Actual): November 30, 2024
• Study Completion (Actual): January 15, 2025

Study Registration Dates

• First Submitted: January 11, 2022
• First Submitted That Met QC Criteria: January 10, 2024
• First Posted (Actual): January 12, 2024

Study Record Updates

• Last Update Posted (Estimated): May 20, 2025
• Last Update Submitted That Met QC Criteria: May 15, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Keywords: antioxidants; ivf; oocyte quality assessment; oocyte scoring
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Infertility
• Other Study ID Numbers: UHR-17

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No